CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line ...

Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December ...

Anika Therapeutics Inc (ANIK) reports robust revenue growth and improved margins, despite facing regulatory and pricing challenges in Q4 2025.

Q4 2025 earnings call: 2026 revenue outlook, 22% commercial growth, cost cuts, margins & pipeline updates—read key takeaways.

Anika Therapeutics, Inc. ( ANIK) Q4 2025 Earnings Call February 26, 2026 8:30 AM EST Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year-End Earnings Conference Call.

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.25 per share a year ago. These ...

Anika Therapeutics develops and manufactures medical products using hyaluronic acid (HA), a naturally occurring molecule that aids in lubrication and tissue healing. Its main product families target ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Anika Therapeutics, Inc. (NASDAQ:ANIK) stands against the other ...

NEW YORK, Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ: ANIK). Such investors are advised ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Anika Therapeutics develops and manufactures medical ...